Thursday, February 27, 2014

Daily Dose - Oncogenex, Merrimack, KaloBios

A number of buy recommendations came out this morning for some of my holdings and one reports earnings after market close. 

Oncogenex OGXI was upgraded to buy by CRT Capital with a $20 price target.  Oncogenex will report phase 3 results of it's prostate cancer drug, Custirsen, sometime in Q2.  The stock has a discounted market cap of $172 million for a company with three phase 3 and seven phase 2 trials running which is why I hold a significant position. 

OGXI

 
11.695  


5,000   $11.01   $3,377.46   6.13%   $58,475.00
KaloBios KBIO was upgraded to buy by JMP Securities with a $8 price target.  The company took a recent hit after it's flagship Asthma drug failed in a phase 2 study but the company has other compounds with promise and great partnerships with Sanofi and Novartis so I'm looking to buy at these levels.

Merrimack MACK will report Q4 and full year results after the bell today.  The stock has been on a tear since pushing back expected results from it's pancreatic cancer drug, MM-398, about six months due to longer overall survival trends.   Merrimack is my pick up the year as pancreatic cancer is one of the deadliest and has few treatment options (think the late Patrick Swayze) so a survival benefit would be outstanding for patients and for the Merrimack.

MACK

 
5.005  


15,400   $2.9977   $30,871.84   66.81%   $77,077.00  






















































































No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com